The distribution of non-Hodgkin lymphoma subtypes varies around the world, but a large
systematic comparative study has never been done. In this study, we evaluated the clinical …

Background The addition of rituximab to combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved …

Background Despite advances in treatments for Hodgkin's lymphoma, about 20% of
patients still die from progressive disease. Current prognostic models predict the outcome of …

Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is crucial because these two types of lymphoma require different treatments. We examined …

Bone marrow specimens from 317 patients with non-Hodgkin's lymphoma (NHL) obtained at
initial staging were evaluated for the presence of lymphoma or benign lymphoid aggregates…

Purpose The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the
search for new markers that can accurately separate prognostic risk groups. We previously …

… Therefore, we believe that our analysis provides the best available evidence to address the
benefit of autoSCT in CR1 in patients with DHL, as well as the durability of CR1 on the basis …

… The reason, Michael Best shows, is the rigid command and control structures that are typical
… Best envisions a new role for national industrial policy-one not of bailing out sick firms in …

… Transects were 30 or 60 m long, with longer transects in less dense stands. We measured
the stem diameter of each white spruce within 2.5 m of the transect, except at one burned site …

The clinical usefulness of histologic grading in follicular lymphoma (FL) is controversial and
is further compromised by the subjective nature and poor reproducibility of most systems in …